nach oben

Supportive Care in Cancer

Erschienen in:

01.12.2015 | Commentary

The financial hazard of personalized medicine and supportive care

verfasst von: Pricivel M. Carrera, Ian Olver

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Personalized medicine is revolutionizing the delivery of oncological care, promising benefits both at the patient and health system levels. The cost of targeted therapies, unfortunately, is becoming more expensive and unaffordable. Where supportive care in cancer concerns the prevention and management of the adverse effects of cancer and its treatment and is the thrust of the Multinational Association of Supportive Care in Cancer, financing of and value in personalized medicine is an important area of research and engagement for the association. Discussing patients’ concerns with and identifying those at most risk for the financial hazard of cancer treatment and offering financial counseling and assistance and/or referral to support networks are potential key areas for (exploring and providing) better supportive care. The time is now to turn the concern of patients and their carers, providers, and other advocates regarding the affordability of cancer treatment into a collective cause towards coordinated action.

Stahel R, Peters S, Baas P et al (2013) Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 82:375–382CrossRefPubMed

Carrera P, Ormond M (2015) Current practice in and considerations for personalized medicine in lung cancer: from the patient’s molecular biology to patient values and preferences. Maturitas 82:94–99

Zafar SY, Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park) 27:80–81, 149

Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D (2014) High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract 10:e208–e211CrossRefPubMed

Tucker-Seeley RD, Abel GA, Uno H, Prigerson H (2014) Financial hardship and the intensity of medical care received near death. Psychooncology 24:572–578CrossRefPubMed

Shen YC, McFeeters J (2006) Out-of-pocket health spending between low-and higher-income populations: who is at risk of having high expenses and high burdens? Med Care 44:200–209CrossRefPubMed

Himmelstein DU, Thorne D, Warren E, Woolhandler S (2009) Medical bankruptcy in the United States, 2007: results of a national study. Am J Med 122:741–746CrossRefPubMed

Linley WG, Hughes DA (2013) Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 22:948–964CrossRefPubMed

Kentikelenis A, Karanikolos M, Reeves A, McKee M, Stuckler D (2014) Greece’s health crisis: from austerity to denialism. Lancet 383(9918):748–753CrossRefPubMed

10.

Saloustros E, Vichas G, Margiolaki A, Koumiotaki S, Androulakis N, Georgoulias V (2014) Lung cancer in the era of Greek economic crisis. Lung Cancer 86(1):112–113CrossRefPubMed

11.

Rittenberg CN, Johnson JL, Kuncio GM (2010) An oral history of MASCC, its origin and development from MASCC’s beginnings to 2009. Support Care Cancer 18:775–784CrossRefPubMed

12.

Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874CrossRefPubMed

13.

Olver I (2013) Challenges of accessing cancer medicines in Australia. Lancet Oncol 11:1040–1042CrossRef

14.

Smith SK, Nicolla J, Zafar SY (2014) Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. J Oncol Pract 10:e368–e372CrossRefPubMed

15.

Chan A, Chiang YY, Low XH, Yap KY, Ng R (2013) Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. Support Care Cancer 21:3509–3517CrossRefPubMed

16.

Prawitz AD, Garman ET, Sorhaindo B et al (2006) InCharge Financial Distress/Financial Well-Being Scale: development, administration, and score interpretation. J Financ Couns Plan 17:34–50

17.

de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120:3245–3253CrossRefPubMed

18.

Teng I, Spigelman A (2014) Attitudes and knowledge of medical practitioners to hereditary cancer clinics and cancer genetic testing. Fam Cancer 13(2):311–324CrossRefPubMed

19.

Henrikson NB, Tuzzio L, Loggers ET, Miyoshi J, Buist DS (2014) Patient and oncologist discussions about cancer care costs. Support Care Cancer 22:961–967PubMedCentralCrossRefPubMed

20.

Schnipper LE, Davidson NE, Wollins DS et al (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. doi:10.1200/JCO.2015.61.6706 PubMed

Titel: The financial hazard of personalized medicine and supportive care
verfasst von: Pricivel M. Carrera
Ian Olver
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 12/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2922-3

Springer Medizin

The financial hazard of personalized medicine and supportive care

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw

Feasibility of Cognitively-Based Compassion Training (CBCT) for breast cancer survivors: a randomized, wait list controlled pilot study

Cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services

The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review

Validation of Chinese and English versions of the Holistic Well-being Scale in patients with cancer

Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie